APOGEE THERAPEUTICS INC (APGE) Stock Fundamental Analysis

NASDAQ:APGE • US03770N1019

70.89 USD
-0.38 (-0.53%)
At close: Feb 25, 2026
70.78 USD
-0.11 (-0.16%)
Pre-Market: 2/26/2026, 4:05:38 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, APGE scores 3 out of 10 in our fundamental rating. APGE was compared to 521 industry peers in the Biotechnology industry. APGE has a great financial health rating, but its profitability evaluates not so good. APGE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year APGE has reported negative net income.
  • APGE had a negative operating cash flow in the past year.
APGE Yearly Net Income VS EBIT VS OCF VS FCFAPGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • With a Return On Assets value of -40.51%, APGE perfoms like the industry average, outperforming 57.97% of the companies in the same industry.
  • The Return On Equity of APGE (-43.26%) is better than 69.10% of its industry peers.
Industry RankSector Rank
ROA -40.51%
ROE -43.26%
ROIC N/A
ROA(3y)-23.75%
ROA(5y)N/A
ROE(3y)-25.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APGE Yearly ROA, ROE, ROICAPGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

  • APGE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APGE Yearly Profit, Operating, Gross MarginsAPGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, APGE has more shares outstanding
  • APGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APGE Yearly Shares OutstandingAPGE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
APGE Yearly Total Debt VS Total AssetsAPGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • APGE has an Altman-Z score of 71.35. This indicates that APGE is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 71.35, APGE belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
  • APGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 71.35
ROIC/WACCN/A
WACCN/A
APGE Yearly LT Debt VS Equity VS FCFAPGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 15.86 indicates that APGE has no problem at all paying its short term obligations.
  • APGE has a Current ratio of 15.86. This is amongst the best in the industry. APGE outperforms 92.51% of its industry peers.
  • APGE has a Quick Ratio of 15.86. This indicates that APGE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of APGE (15.86) is better than 92.51% of its industry peers.
Industry RankSector Rank
Current Ratio 15.86
Quick Ratio 15.86
APGE Yearly Current Assets VS Current LiabilitesAPGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • APGE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -81.22%.
EPS 1Y (TTM)-81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -7.51% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-30.72%
EPS Next 2Y-24.64%
EPS Next 3Y-23.31%
EPS Next 5Y-7.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APGE Yearly Revenue VS EstimatesAPGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
APGE Yearly EPS VS EstimatesAPGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for APGE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APGE Price Earnings VS Forward Price EarningsAPGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APGE Per share dataAPGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • APGE's earnings are expected to decrease with -23.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.64%
EPS Next 3Y-23.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • APGE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APOGEE THERAPEUTICS INC

NASDAQ:APGE (2/25/2026, 8:00:01 PM)

Premarket: 70.78 -0.11 (-0.16%)

70.89

-0.38 (-0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-10
Inst Owners110.75%
Inst Owner Change12.89%
Ins Owners2.2%
Ins Owner Change-7.35%
Market Cap4.84B
Revenue(TTM)N/A
Net Income(TTM)-253.67M
Analysts86.36
Price Target106.37 (50.05%)
Short Float %17.78%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.77%
Min EPS beat(2)-2.92%
Max EPS beat(2)8.47%
EPS beat(4)2
Avg EPS beat(4)5.62%
Min EPS beat(4)-8.41%
Max EPS beat(4)25.36%
EPS beat(8)4
Avg EPS beat(8)6.19%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.87%
PT rev (3m)9.43%
EPS NQ rev (1m)1.26%
EPS NQ rev (3m)4.35%
EPS NY rev (1m)0%
EPS NY rev (3m)6.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.26
P/tB 8.26
EV/EBITDA N/A
EPS(TTM)-4.38
EYN/A
EPS(NY)-5.11
Fwd EYN/A
FCF(TTM)-3.48
FCFYN/A
OCF(TTM)-3.4
OCFYN/A
SpS0
BVpS8.58
TBVpS8.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.51%
ROE -43.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.75%
ROA(5y)N/A
ROE(3y)-25.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 467.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.86
Quick Ratio 15.86
Altman-Z 71.35
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.07%
EPS Next Y-30.72%
EPS Next 2Y-24.64%
EPS Next 3Y-23.31%
EPS Next 5Y-7.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-59.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.87%
EBIT Next 3Y-22.04%
EBIT Next 5Y-9.37%
FCF growth 1Y-129.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.96%
OCF growth 3YN/A
OCF growth 5YN/A

APOGEE THERAPEUTICS INC / APGE FAQ

What is the ChartMill fundamental rating of APOGEE THERAPEUTICS INC (APGE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to APGE.


Can you provide the valuation status for APOGEE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to APOGEE THERAPEUTICS INC (APGE). This can be considered as Overvalued.


Can you provide the profitability details for APOGEE THERAPEUTICS INC?

APOGEE THERAPEUTICS INC (APGE) has a profitability rating of 1 / 10.


How financially healthy is APOGEE THERAPEUTICS INC?

The financial health rating of APOGEE THERAPEUTICS INC (APGE) is 8 / 10.